[This announcement contains inside information] 9 July 2026 Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not...
1 July 2026 Notification of Admission of Further Securities to Trading (PRM 1.6.4R) The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R....
1 July 2026 Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 June 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,024,534 ordinary shares of US$0.25. No shares are held in Treasury....
29 June 2026 Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which demonstrated clinically meaningful responses across a broad range of tumours...
29 June 2026 Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy Recommendation based on TROPION-Breast02 Phase III trial where AstraZeneca and Daiichi Sankyo's Datroway showed a statistically significant and clinically meaningful...
15 June 2026 Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed Truqap combination reduced risk of radiographic disease progression or death by 19% First-in-class AKT...
1 June 2026 Notification of Admission of Further Securities to Trading (PRM 1.6.4R) The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R....
1 June 2026 Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 May 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,009,750 ordinary shares of US$0.25. No shares are held in Treasury....
29 May 2026 Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer Based on POTOMAC Phase III trial results which showed a 32% reduction in the risk of high-risk disease recurrence, progression or death after one year of Imfinzi added to BCG vs....
27 May 2026 US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data The US Food and Drug Administration (FDA) has informed AstraZeneca that it will extend the Prescription Drug User Fee Act (PDUFA) date to review additional data requested to support the New Drug Application (NDA) for camizestrant in combination...
26 May 2026 Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer Recommendation based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumour mutation If approved,...
26 May 2026 Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which showed clinically meaningful responses across a broad range of tumours If approved, Enhertu would become the first HER2-directed therapy...
26 May 2026 Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates AstraZeneca and Daiichi Sankyo's Datroway is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs....
18 May 2026 Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 14 May 2026, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to Pascal Soriot, Executive Director and Chief Executive Officer, under the terms of the AstraZeneca Performance Share Plan (AZPSP)....
18 May 2026 Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial Two new indications bring AstraZeneca and Daiichi Sankyo's Enhertu into curative-intent...
18 May 2026 Baxfendyapproved in the US as the first and only aldosterone synthase inhibitortreatment for adults with hypertension Approval based on BaxHTN Phase III results showing statistically significant and clinically meaningful reduction in systolic blood pressure in patients with uncontrolled or resistant hypertension Baxfendy 2mg lowered systolic...
14 May 2026 Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial Perioperative Imfinzi plus Imjudo and neoadjuvant EV showed a statistically significant and clinically meaningful improvement...
1 May 2026 Total Voting Rights and Notification of Admission of Further Securities to Trading (PRM 1.6.4R) Total Voting Rights The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1....
01 May 2026 Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote in favor of the benefit risk profile of AstraZeneca's camizestrant in combination with a...
01 May 2026 Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer ODAC overwhelming majority voted that Truqap plus abiraterone and ADT demonstrated a favourable benefit risk profile for patients based on the CAPItello-281 Phase III trial results First and only targeted treatment combination to...
29 April 2026 AstraZeneca results: Q1 2026 Strong revenue growth and positive readouts from high-value NMEs reinforce confidence in 2030 ambition Revenue and EPS summary [][] Q1 2026 % Change $m Actual CER[1] - Product Sales 14,386 12 7 - Alliance Revenue 825 29 26 Product Revenue 15,211 13 8 Collaboration Revenue 77 4 - Total Revenue 15,288 13 8 Reported...
28 April 2026 Breztri approved in the US for asthma as first and only triple therapy for patients 12 years of age and older Approval based on KALOS and LOGOS Phase III trials demonstrating statistically significant and clinically meaningful benefits of AstraZeneca's single-inhaler fixed-dose triple therapy compared with inhaled dual therapy Approval is...
27 April 2026 Saphnelo approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus First-in-class Saphnelo Pen now offers greater flexibility and convenience, reaching a wider group of patients AstraZeneca's Saphnelo (anifrolumab) has been approved in the US for self-administration as a...
23 April 2026 Change to AstraZeneca Board of Directors AstraZeneca congratulates Rene Haas on his appointment as Chief Executive Officer of SoftBank Group International, in addition to his position as Chief Executive Officer of Arm Holdings plc....
21 April 2026 Ultomiris demonstrated statistically significant and clinically meaningful reduction of proteinuria in adults with immunoglobulin A nephropathy in I CAN Phase III trial Ultomiris delivered rapid reduction in proteinuria as early as week 10 Results show potential for terminal C5 complement inhibition with Ultomiris as a disease-modifying...